BRIDGEWATER, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- Nevakar Injectables Inc. (“Nevakar”), a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings, and announced today that the U.S. Food and Drug Administration (“FDA”) has approved its ready-to-use Ephedrine Sulfate Injection (“Ephedrine”) in a prefilled syringe (“PFS”). This product is an ephedrine formulation prediluted to a 5mg/mL concentration and supplied in a ready-to use 5mL PFS. It will be marketed and sold in the U.S. by the Par Sterile Products (“Par”) business of Endo International plc (“Endo”) (NASDAQ: ENDP). Ephedrine is a widely used injectable vasopressor agent indicated for the treatment of clinically important hypotension occurring during surgery.
Last month, Nevakar announced the launch of its ready-to-use ephedrine prediluted vial. With the added approval of the ephedrine prefilled syringe, Nevakar and Endo aim to offer a portfolio of ephedrine products to health care professionals treating patients in the surgical setting.
About Nevakar Injectables, Inc. Nevakar Injectables, Inc. is a wholly owned subsidiary of Nevakar, Inc., a fully integrated privately held, late-stage biopharmaceutical company with an extensive portfolio of products in the ophthalmic and injectable areas. Nevakar Injectables is developing a broad portfolio of injectable products for use in the hospital and ambulatory care settings. The Company has active programs in critical patient care, acute pain management, long acting injectables, and hospital injectables. For additional information please visit www.nevakarinjectables.com.
About Endo Endo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from passionate team members around the globe collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Learn more at www.endo.com or connect with us on LinkedIn.
About Par Pharmaceutical Par Pharmaceutical develops, manufactures and markets safe, innovative and cost-effective generic pharmaceutical and branded injectable products that help improve patient quality of life. Par, among the top leaders in the U.S. generics industry, possesses an expanding portfolio that includes sterile injectables, alternative dosage forms and other differentiated products. Par Pharmaceutical is an Endo company. Learn more at www.parpharm.com.
Marshall Woodworth Chief Financial Officer (908) 699-4940 E: mwoodworth@nevakar.com
Lisa M. Wilson In-Site Communications, Inc. T: (212) 452-2793 E: lwilson@insitecony.com
Fight back against inflation. This is how Dalio does it.
These rapidly growing stocks are begging to be bought following a more than 30% peak decline in the Nasdaq.
Will we have enough to ‘live a simple life’ in retirement? Many other retirees wonder the same thing as you, and may be in similar financial circumstances where they’re able to pay the bills and have money saved in their retirement accounts. Your interest rate is fantastic, you’re capable of making the monthly payment from just your pension and Social Security without tapping into your 401(k) and you have so much of your home already paid off — all wins.
Whether you're looking for household goods at discounted prices or need to buy your grocery items in bulk, Costco is the go-to retailer for millions of shoppers across the U.S. But despite its ability to attract a loyal following, Costco has made a number of changes recently that haven't thrilled customers. In April, the warehouse retailer got rid of its special COVID hours for seniors, and just this month, Costco ended its mortgage program for members. Now, the retailer has a new warning for sh
The stock market pulled back from the brink of a bear market as rate-hike expectations eased, at least for now. Here's what it will take to signal a bottom.
Despite all the attention that renewable energy companies get, having operations in the renewable energy space alone does not make a stock a buy. In fact, several renewable energy companies are struggling just to stay profitable. Let's discuss two renewable energy stocks that look attractive right now, and one that's best avoided.
What happened Shares of drugmaker Novavax (NASDAQ: NVAX) are up to the tune of 18.9% as of 2:11 p.m. ET Friday, according to data from S&P Global Market Intelligence, thanks to a confluence of events that work in the company's favor.
Many Americans are surprised to see they have not prepared as well as they had hoped for retirement when they finally get ready to call it quits. The bad news is, you’ll probably have to make some realistic assumptions of what your retirement will look like. If you’ve lived primarily paycheck to paycheck in your working years, that may continue to feel the case in your retirement.
Financial technology company Upstart Holdings (NASDAQ: UPST) has proven to be one of the most volatile stocks on Wall Street since going public at the end of 2020. Investors were shocked when Upstart's 2022 first-quarter earnings report revealed a surge in loans on the company's balance sheet, a potentially risky situation in an economy that appears to be slowing. Upstart receives a fee for the loans it touches, making it more a technology platform than an actual lender.
The market is unstable. Your portfolio doesn’t need to be.
Markets are shaky. Your income stream doesn’t have to be.
The stock market is a game of risk and calculation, and in recent months the risks are mounting. The first quarter of 2022 showed a net negative GDP growth rate, a contraction of 1.4%; another contraction in Q2 will indicate a recession. Wall Street’s experts are trying to look ahead, to see through the fog of uncertainty and get some feel for where things are going. Covering the market for Morgan Stanley, chief US equity strategist Michael Wilson believes that we’ll dodge the recession bullet –
Stocks have been inching back in recent days from the brink of bear market territory. It may be time to scoop up shares at steep discounts.
The stock market selloff has made many stocks look cheap—but smart investors need to be selective. Here are six high-quality companies that trade at reasonable valuations.
Here's what a fundamental and technical analysis says about Google stock. GOOGL stock buybacks remain high as web search and YouTube advertising rebound. But cloud computing growth is key.
(Bloomberg) -- Most Read from BloombergRussian Wins in Eastern Ukraine Spark Debate Over Course of WarElon Musk Says Bill Gates Has ‘Multi-Billion Dollar’ Tesla Short PositionFord Beats Tesla to the Punch With First Electric F-150 DeliveryZilingo’s Fired CEO Responds to Questions of Mystery PaymentsBitcoin Breaks From Stocks and Keeps On Falling as Crypto SlidesPresident Vladimir Putin spoke with the leaders of Germany and France, who urged an immediate cease-fire and for Moscow to free the figh
Choosing between two depends on whether you'd rather pay taxes now, or later.
In this article, we discuss the 10 stocks that Jim Cramer and hedge funds agree on. If you want to read about some more stocks that Jim Cramer and hedge funds agree on, go directly to Jim Cramer and Hedge Funds Agree on These 5 Stocks. In the past few weeks, Jim Cramer, the journalist […]
Don't make the same mistake as Zillow when you try to price a home.
Yahoo Finance's Pras Subramanian test drives the all-electric Mercedes-Benz EQS 580 4Matic sedan.